July 25, 2025Frontiers in ImmunologyOpen Access

Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Meta-analysis shows superior outcomes for TACE-L-P over TACE-L in HCC, suggesting enhanced treatment strategies in advanced cases.

TACE-L-P improved overall survival and progression-free survival compared to TACE-L in advanced hepatocellular carcinoma.
The objective response rate and disease control rate were significantly higher with TACE-L-P group.
In total, 2002 patients participated in the 19 studies examined in the meta-analysis.
Although TACE-L-P was more effective, it also increased the rate of grade ≥ 3 treatment-related adverse events.

Lei et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

July 25, 2025Frontiers in ImmunologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis shows superior outcomes for TACE-L-P over TACE-L in HCC, suggesting enhanced treatment strategies in advanced cases.

TACE-L-P improved overall survival and progression-free survival compared to TACE-L in advanced hepatocellular carcinoma.
The objective response rate and disease control rate were significantly higher with TACE-L-P group.
In total, 2002 patients participated in the 19 studies examined in the meta-analysis.
Although TACE-L-P was more effective, it also increased the rate of grade ≥ 3 treatment-related adverse events.

Lei et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark